Application of microfluidic technologies on COVID-19 diagnosis and drug discovery  

作　　者：Zhun Lin Zhengyu Zou Zhe Pu Minhao Wu Yuanqing Zhang 

机构地区：[1]School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou 510006,China [2]Zhongshan School of Medicine,Sun Yat-sen University,Guangzhou 510080,China

出　　处：《Acta Pharmaceutica Sinica B》2023年第7期2877-2896,共20页药学学报（英文版）

基　　金：support from the National Natural Science Foundation of China(82072087,31970893,32270976);funding by Science and Technology Projects in Guangzhou(202206010087,China)。

摘　　要：The ongoing coronavirus disease 2019(COVID-19) pandemic has boosted the development of antiviral research.Microfluidic technologies offer powerful platforms for diagnosis and drug discovery for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) diagnosis and drug discovery.In this review,we introduce the structure of SARS-CoV-2 and the basic knowledge of microfluidic design.We discuss the application of microfluidic devices in SARS-CoV-2 diagnosis based on detecting viral nucleic acid,antibodies,and antigens.We highlight the contribution of lab-on-a-chip to manufacturing point-ofcare equipment of accurate,sensitive,low-cost,and user-friendly virus-detection devices.We then investigate the efforts in organ-on-a-chip and lipid nanoparticles(LNPs) synthesizing chips in antiviral drug screening and mRNA vaccine preparation.Microfluidic technologies contribute to the ongoing SARSCoV-2 research efforts and provide tools for future viral outbreaks.

关 键 词：Microfluidic COVID-19 SARS-CoV-2 LAB-ON-A-CHIP Detection Organ-on-a-chip Drug screen 

分 类 号：R563.1[医药卫生—呼吸系统] TQ460.1[医药卫生—内科学]